FibroGen Announces Completion of Patient Enrollment in LELANTOS-2, a Phase III Clinical Study of Pamrevlumab in Duchenne Muscular Dystrophy
FibroGen, Inc. announced completion of patient enrollment for LELANTOS-2, a Phase III clinical study of pamrevlumab in patients with ambulatory Duchenne muscular dystrophy.
[Cancer Communications] Scientists designed a novel CAR-natural killer cells with a clinically significant tumoricidal effect on castration-resistant prostate cancer.
[Journal of Orthopaedic Surgery and Research] The authors showed that both cell-free and stem cell-seeded scaffolds exhibited superb healing compared with the empty defect controls, and new bone and connective tissues were formed in the healing site after 8 and 12 weeks, postoperatively.
[Communications Biology] Double bioluminescent/fluorescent Leishmania infantum and L. donovani reporter lines enabled the identification of long-term hematopoietic stem cells as a niche in the bone marrow with remarkably high parasite burdens, a feature confirmed for human hematopoietic stem cells.